In IPSOS trial Presented by Dr. Siow Ming Lee, 1L #atezolizumab significantly improved OS vs single-agent chemo in platinum-ineligible pts with metastatic NSCLC without driver mutations. In this phase III trial, Atezo significantly improved 2-yr OS rate (stratified HR, 0.78; P=0.028). Additionally, benefit was seen in ORR and DOR with fewer Gr 3/4 TRAEs which occurred in 16.3% of pts in Atezo arm vs 33.3% in chemo arm.
.png)